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Abstract 
Background: Little evidence exists on the health effects of e‑cigarette use. DNA methylation may serve as a bio‑
marker for exposure and could be predictive of future health risk. We aimed to investigate the DNA methylation 
profile of e‑cigarette use.
Results: Among 117 smokers, 117 non‑smokers and 116 non‑smoking vapers, we evaluated associations between 
e‑cigarette use and epigenome‑wide methylation from saliva. DNA methylation at 7 cytosine‑phosphate‑guanine 
sites (CpGs) was associated with e‑cigarette use at p < 1 ×  10–5 and none at p < 5.91 ×  10–8. 13 CpGs were associated 
with smoking at p < 1 ×  10–5 and one at p < 5.91 ×  10–8. CpGs associated with e‑cigarette use were largely distinct 
from those associated with smoking. There was strong enrichment of known smoking‑related CpGs in the smokers 
but not the vapers. We also tested associations between e‑cigarette use and methylation scores known to predict 
smoking and biological ageing. Methylation scores for smoking and biological ageing were similar between vapers 
and non‑smokers. Higher levels of all smoking scores and a biological ageing score (GrimAge) were observed in 
smokers. A methylation score for e‑cigarette use showed poor prediction internally (AUC 0.55, 0.41–0.69) and exter‑
nally (AUC 0.57, 0.36–0.74) compared with a smoking score (AUCs 0.80) and was less able to discriminate lung squa‑
mous cell carcinoma from adjacent normal tissue (AUC 0.64, 0.52–0.76 versus AUC 0.73, 0.61–0.85).
Conclusions: The DNA methylation profile for e‑cigarette use is largely distinct from that of cigarette smoking, did 
not replicate in independent samples, and was unable to discriminate lung cancer from normal tissue. The extent to 
which methylation related to long‑term e‑cigarette use translates into chronic effects requires further investigation.
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Introduction
Electronic cigarettes (e-cigarettes) have the potential to 
reduce smoking-related harm. Although little evidence 
currently exists on long-term effects, their lack of tar and 
very low levels of other dangerous substances [1] sug-
gest they are considerably less harmful than cigarettes 
[2]. They have been shown to be an efficacious [3] and 
cost-effective [4] smoking cessation aid. While it will take 
years to fully estimate the impact of e-cigarette use on 
diseases including cancer, we can investigate whether it 
is associated with any biomarkers that may predict future 
health risk [5]. Recent studies have found a reduction in 
harmful biomarkers among e-cigarette users (vapers) 
compared with smokers, with some biomarkers showing 
levels similar to non-smokers [5–7]. However, only a few 
biomarkers have been investigated and all with relatively 
short half-lives [8, 9], meaning their utility for predicting 
long-term effects of e-cigarettes may be limited.
DNA methylation is a type of epigenetic modifica-
tion involving the addition of methyl groups to the 
DNA which influences how the underlying sequence is 
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interpreted and expressed. Pronounced differences in 
methylation have been found between cigarette smok-
ers and non-smokers [10]. These have been replicated in 
different populations [11, 12] and tissues [13], shown to 
persist for several years post-cessation [10], are able dis-
tinguish tumour from normal samples [14], and are pre-
dictive of disease and mortality [15, 16]. Assessing the 
methylation profile of vaping could therefore inform our 
understanding of the potential biological impact of their 
use and the relative health risks compared to cigarettes 
[17].
In this study, we explored whether e-cigarette use 
is associated with methylation in saliva and evaluated 
the degree of similarity between methylation profiles in 
vapers and cigarette smokers (compared with non-smok-
ers). The investigation of methylation in saliva is sup-
ported by the overlap in methylation signals related to 
smoke exposure in blood and saliva [18], with one study 
demonstrating a stronger signal in buccal samples com-
pared with matched blood samples [14]. We investigated 
associations between e-cigarette use and previously-
developed methylation scores used to predict smoking-
related disease and mortality [12, 16], and biological 
ageing [19, 20]. We generated a novel methylation score 
for predicting e-cigarette use and assessed replication in 
an independent study. We also investigated whether the 
e-cigarette score was able to distinguish lung tumour and 
adjacent normal tissue to the same extent as a smoking 
score, in order to make inferences about the potential 
importance of e-cigarette-related methylation in lung 
cancer development.
Methods
The analysis plan was pre-registered [21] and is summa-
rized in Additional file 1: Figure 1.
Study Design
The SEE-Cigs study (Studying the Epigenetics of E-cig-
arette Use) recruited vapers, smokers and non-smokers 
from the United Kingdom general population. It was 
important that vapers did not have a long previous smok-
ing history, given the persistence of methylation marks 
associated with smoke exposure many years after ces-
sation [10, 22]. Vapers were therefore defined as having 
used e-cigarettes at least weekly for the past 6  months 
and having smoked < 100 times in their lifetime; smokers 
as having smoked at least weekly for the past 6 months 
and having used an e-cigarette < 100 times in their life-
time; and never smokers as having smoked and/or used 
an e-cigarette < 100 times in their lifetime. We aimed to 
recruit 120 participants per group (vapers, smokers, non-
smokers) to provide > 80% power to detect a 4.5% mean 
difference in methylation at p < 0.05 and > 80% power to 
detect an 11% mean difference at p < 1 ×  10–6.
Eligibility criteria
In order to maximise the chance that vapers had never 
been cigarette smokers, and to minimize confounding by 
age, we restricted eligibility to between 16 and 35 years 
old. Additional inclusion criteria were that the partici-
pants were in good physical and mental health (measured 
via self-report) and were able to give informed consent as 
judged by the investigator. Exclusion criteria obtained via 
self-report were: dependence on alcohol or drugs (other 
than nicotine); significant current or past illness (includ-
ing cancer and type 1/type 2 diabetes); current pregnancy 
or breast feeding; having a related individual in the sam-
ple [21].
Recruitment
Participants were recruited via a number of mechanisms 
including from the student population at the University 
of Bristol, podcasts, blogs, posters/flyers in vape shops, 
and social media. Recruitment began in January 2017 
and was completed in January 2019. The study protocol 
was originally published on the Open Science Frame-
work on 19/01/2017. On 06/02/2018 we were granted 
ethics approval to relax the eligibility criteria related 
to age (16–35  years), and previous smoking history of 
the vapers and never-smokers (< 100 cigarettes in their 
lifetime) and vaping history of the smokers and never-
smokers (vaped < 100 times in their lifetime). We stated 
in our original protocol that we would relax age criteria 
if recruitment stalled. Ethics approval for the study was 
granted by the Faculty of Science Human Research Ethics 
Committee at the University of Bristol.
Consent
All participants have provided written informed consent.
Questionnaire
Participants answered questions about their smoking 
and vaping behavior, as well as socio-demographic and 
behavioural factors including age, gender, height and 
weight (from which body mass index (BMI) was calcu-
lated), ethnicity, educational attainment, occupation 
and household smoking. They were asked whether they 
currently used recreational drugs and if so, which recre-
ational drugs they used (stimulants, cocaine, opiates, hal-
lucinogens, cannabis, MDMA/ecstasy). Based on initial 
responses to the questionnaire, and in accordance with 
the eligibility criteria, participants were allocated to three 
participant groups (smokers, vapers and never-smok-
ers). Participants in the ‘smokers’ category were asked 
whether they smoke cigarettes or roll-ups, whether they 
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were daily or weekly smokers, and how many cigarettes 
they smoked per day/week as appropriate. They were 
asked at what time of day they smoke their first cigarette, 
for how long they had been a smoker, and details about 
whether they had plans to give up, or whether they had 
previously attempted to stop smoking. Participants in 
the ‘vapers’ category were asked about the type of device 
they used, the nicotine concentration they used most fre-
quently, and whether they had changed the nicotine con-
centration in the past. If they reported using a refillable 
device, they were asked to estimate the volume of liquid 
used in an average day. Similar to the ‘smokers’ group, 
this group were asked the time of day that they first 
vape, how long they had been a vaper, and details about 
whether they had plans to give up vaping. Participants in 
the ‘never-smokers’ group were asked whether they had 
ever smoked or vaped, and how frequently, to ensure 
they met our inclusion/exclusion criteria.
Sample collection
After completing an online questionnaire, partici-
pants were screened for eligibility and sent an informa-
tion sheet and consent form. On enrolling, participants 
were posted a study pack containing a saliva collection 
kit (DNA Genotek Oragene™) from which DNA was 
extracted and methylation was measured. We supple-
mented existing kit instructions with a simplified ver-
sion to aid understanding and improve sample quality, 
which was posted to participants along with the kit, con-
sent form and information sheet. We asked participants 
to provide 2 mL of saliva and return the kits through the 
post to the University of Bristol, where they were pro-
cessed by the Bristol Bioresource Laboratories.
DNA methylation profiling
DNA was extracted from the saliva samples and under-
went bisulphite conversion using the Zymo EZ DNA 
Methylation™ kit (Zymo, Irvine, CA). Genome-wide 
methylation status of over 850,000 cytosine-phosphate-
guanine sites (CpGs) was measured using the Illumina 
HumanMethylationEPIC array according to standard 
protocol. DNA samples were loaded onto the Illumina 
HumanMethylationEPIC array in three batches with sam-
pling criteria in place to ensure that all three groups were 
represented in each batch in order to minimise poten-
tial confounding by batch effects. In addition, during the 
data generation process a wide range of batch variables 
were recorded in a purpose-built laboratory information 
management system (LIMS), which also reported quality 
control (QC) metrics. Microarray data underwent qual-
ity control and normalization using meffil, an R package 
designed for pre-processing of large samples of Illumina 
Methylation BeadChip microarrays [23]. Sample outliers 
were identified and removed based on sex-chromosome 
methylation, methylation versus unmethylation intensity, 
control probes, detection p values (N = 10 exclusions in 
total: 4 vapers, 3 smokers and 3 non-smokers). Poor qual-
ity CpG sites, SNP/control probes and CpGs on the sex 
chromosomes were excluded, resulting in 846,244 CpG 
sites for analysis.
Estimated cell type proportions
A cell type reference for saliva was derived as part of 
meffil by combining a white blood cell type reference 
(GEO: GSE35069) and a buccal cell type reference (GEO: 
GSE48472). Estimated cell type proportions comprised: 
Buccal, CD4T, CD8T, Monocytes, B-cells, NK cells and 
Granulocytes.
Statistical analysis
Epigenome‑wide association study (EWAS)
Multivariable linear regression was used to assess the dif-
ferences in methylation at each measured CpG between 
(1) vapers versus non-smokers, (2) smokers versus non-
smokers, and (3) smokers versus vapers, with adjustment 
for age, biological sex, BMI, educational attainment, 
household smoking, recreational drug use and 20 sur-
rogate variables, using meffil [23]. We investigated CpGs 
which reached a Bonferroni-significance threshold of 
p < 5.91 ×  10–8 (0.05/846,244 CpGs tested), as well as a 
less stringent threshold of p < 1 ×  10–5. From these EWAS 
results, we identified differentially methylated regions 
(DMRs) using the dmrff R package [24]. DMRs were 
defined as regions containing at least two CpGs within 
500  bp, each with EWAS meta-analysis p values < 0.05 
and methylation changes in a consistent direction, 
and where the regional p value surpassed Bonferroni 
correction.
For the EWAS of vapers versus non-smokers, five 
additional models were run: (i) with adjustment for esti-
mated cell type composition, (ii) with adjustment for 
self-reported smoking history (number of cigarettes), (iii) 
with adjustment for methylation at AHRR (cg05575921), 
an objective biomarker of smoke exposure [25], (iv) after 
excluding participants with < 60% salivary methylation at 
AHRR (cg05575921), indicative of a substantial smoking 
history [18], v) restricted to individuals of white ethnicity.
For the CpG sites identified in the EWAS of vapers 
versus non-smokers, and smokers versus non-smokers, 
we investigated whether there was evidence of a dose 
response in methylation levels based on the length of 
exposure history (6 months–1 year vs > 1 year for e-ciga-
rette use, 6 months–5 years vs > 5 years for smoking).
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Enrichment and annotation
From the EWAS results of (1) vapers versus non-smok-
ers, and (2) smokers versus non-smokers, we investigated 
evidence for enrichment of associations among 2,623 and 
1,501 smoking-related methylation sites identified in pre-
vious large-scale studies of blood [10] and buccal samples 
[14], using a Wilcoxon rank sum test.
Although we excluded potential participants who 
reported drug dependence, given the widespread use of 
e-cigarettes for inhaling cannabinoids [26] and known 
impact of cannabis on DNA methylation levels [27], we 
assessed whether any of the 15 CpGs identified in an 
EWAS of cannabis [27] were associated with e-cigarette 
use after Bonferroni correction. We also ran an addi-
tional model for the EWAS of vapers versus non-smokers 
with adjustment for reported cannabis use. Further, we 
assessed whether any CpG sites associated with alcohol 
use in a previous EWAS [28] were associated with e-ciga-
rette use after Bonferroni correction.
We also investigated whether there was any evidence 
for replication of 14 CpGs related to e-cigarettes in a 
previous EWAS [29], and assessed the extent to which 
the CpGs identified in our EWAS had been previously 
reported in relation to other traits in two publicly avail-
able repositories [30, 31]. We explored the potential func-
tions of the top 50 CpGs identified in each EWAS via GO 
and KEGG enrichment analysis using the missMethyl R 
package [32].
Methylation scores for smoking and epigenetic ageing
Methylation scores can be derived by summing methyla-
tion values at relevant CpGs previously identified in rela-
tion to a relevant exposure, weighted by the effect sizes 
observed in independent EWAS studies. Five methylation 
scores of smoke exposure [10, 14, 16, 25, 33] and four 
methylation scores of epigenetic ageing [33–36] were 
quantified.
We assessed associations between scores compris-
ing methylation values derived from a weighted average 
of CpG sites found to be related to smoking in previous 
studies. This included scores derived from the CpG sites 
identified in EWAS conducted by Joehanes et  al. [10] 
and Teschendorff et al. [14], as well as 233 and 172 CpG 
sites identified in McCartney et al. [16] and Lu et al. [33] 
respectively. The latter two studies used penalised regres-
sion models of smoking pack-years to identify CpG sites 
most predictive of smoke exposure. Finally, since the CpG 
site, cg05575921 (AHRR) contributed most weight to all 
of the methylation scores and has been proposed as an 
independent biomarker of smoking [25], we investigated 
this site as an additional biomarker. With the exception 
of AHRR, the other scores developed were linear com-
binations of methylation levels at the relevant CpG sites 
weighted by the effect sizes of sites identified in relation 
to smoking from the various studies [10, 14, 16, 33].
For epigenetic ageing, we assessed associations 
between two “first generation” epigenetic clocks derived 
from DNA methylation levels at CpG sites found to be 
strongly associated with chronological age [34, 35], as 
well as two more recently derived clocks: one optimised 
to predict physiological dysregulation (PhenoAge) [36] 
and one optimised to predict lifespan (GrimAge) [33]. To 
generate the epigenetic ageing measures in SEE-Cigs, we 
uploaded DNA methylation data for a subset of CpG sites 
from the Illumina EPIC array to the online DNA Meth-
ylation Age Calculator (https:// dnama ge. genet ics. ucla. 
edu/) developed by the Horvath lab. We also uploaded 
an annotation file, containing data on chronological age, 
sex and tissue type (saliva) for the samples. We were able 
to generate the following epigenetic ageing measures: 
intrinsic epigenetic age acceleration based on Horvath’s 
multi-tissue predictor (IEAA) [34]; extrinsic epigenetic 
age acceleration (EEAA) based on Hannum’s method, 
which up-weights the contribution of blood cell com-
position [37]; PhenoAge [36] and GrimAge [33]. Intrin-
sic epigenetic age acceleration (IEAA) is independent of 
changes in blood cell composition while extrinsic epige-
netic age acceleration (EEAA) incorporates age-related 
changes in blood cell composition. PhenoAge and Grim-
Age can be considered as measures of extrinsic ageing.
Multivariable linear regression was used to assess dif-
ferences in methylation scores between the three groups 
with adjustment for age, sex, BMI, educational attain-
ment, household smoking and recreational drug use. 
Further analyses were restricted to individuals of white 
ethnicity only, with adjustment for methylation-derived 
smoking pack-years in the GrimAge model [33], and with 
adjustment for self-reported smoking history when eval-
uating methylation scores in relation to e-cigarettes.
Methylation score for e‑cigarette use
We generated methylation scores for e-cigarette use 
and smoking within SEE-Cigs and then assessed their 
discriminative performance for predicting e-cigarette 
use and smoking within SEE-Cigs and in an independ-
ent dataset, the Avon Longitudinal Study of Parents 
and Children (ALSPAC) [38–40]. We also investigated 
whether the methylation scores for e-cigarette use was 
able to discriminate tumour from normal tissue in lung 
to the same extent as the methylation score for smoking, 
using data from publicly available methylation data in 
The Cancer Genome Atlas (TCGA) [41].
SEE‑Cigs
For internal validation of the methylation score of e-cig-
arette use, we used a training (2/3 sample of vapers and 
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non-smokers) and testing set (1/3 sample of vapers and 
non-smokers) within the SEE-Cigs study. In the training 
set, we used the glmnet package in R to fit a generalized 
logistic regression via penalized maximum likelihood 
using three-fold cross validation and run 10 times to 
determine a lambda with minimum average error. A 
methylation score was then generated based on the fitted 
object produced. The resulting methylation score com-
prised a sum of the beta-values of the included CpG sites. 
Its performance in predicting e-cigarette use was evalu-
ated in the test set by generating a receiver operator char-
acteristic (ROC) curve and evaluating the area under the 
curve (AUC) derived from the logistic regression model 
using the R package pROC (version 1.16.1). We compared 
the AUC obtained from this model with that from a simi-
lar model for predicting smoking. For this, we derived a 
methylation score for smoking using a training set (2/3 
sample of smokers and non-smokers) and testing set (1/3 
sample of smokers and non-smokers) within SEE-Cigs.
Avon Longitudinal Study of Parents And Children
We next assessed external validation of methylation 
scores for e-cigarette use and smoking in the Avon Lon-
gitudinal Study of Parents and Children (ALSPAC). 
ALSPAC is a large, prospective cohort study based in 
the south-west of England. Pregnant women resident in 
Avon, UK with expected dates of delivery 1st April 1991 
to 31st December 1992 were recruited and detailed infor-
mation has been collected on these women and their off-
spring at regular intervals [38, 39]. Additional offspring 
that were eligible to enroll in the study have been sub-
sequently recruited at the ages of 7 and 18  years [40]. 
The additional enrolment provides a baseline sample of 
14,901 offspring who were alive at 1  year of age. Please 
note that the study website contains details of all the data 
that are available through a fully searchable data diction-
ary and variable search tool (http:// www. brist ol. ac. uk/ 
alspac/ resea rchers/ our- data). Ethical approval for the 
study was obtained from the ALSPAC Ethics and Law 
Committee and the Local Research Ethics Committees. 
Consent for biological samples has been collected in 
accordance with the Human Tissue Act (2004). Informed 
consent for the use of data collected via questionnaires 
and clinics was obtained from participants following the 
recommendations of the ALSPAC Ethics and Law Com-
mittee at the time.
When the offspring were 24 years old, they were invited 
to attend the Focus @ 24 + clinic, which took place 
between June 2015 and October 2017. 4,026 were seen 
at this clinic, where fasting blood samples were taken. 
Blood samples from 570 of the offspring were selected 
for DNA methylation profiling to maximize overlap with 
existing DNA methylation profiles generated collected at 
younger ages as part of the Accessible Resource for Inte-
grated Epigenomic Studies (ARIES) [42]. Following DNA 
extraction, samples were bisulphite-converted using the 
Zymo EZ DNA MethylationTM kit (Zymo, Irvine, CA). 
Genome-wide methylation was then measured using 
Illumina Infinium MethylationEPIC Beadchip arrays. 
The arrays were scanned using an Illumina iScan, with 
initial quality review using GenomeStudio. During the 
data generation process a wide range of batch variables 
were recorded in a LIMS, which also reported quality 
control metrics. Quality control and normalization was 
then carried out using the meffil R package [23]. Quality 
control included checks for sample swaps using genotype 
matching and sex prediction, methylated versus unmeth-
ylated signal outliers, dye bias, poor probe signal detec-
tion, and low bead numbers. Only one sample failed and 
was excluded due to evidence of being a sample swap and 
having multiple control probe outliers. The 569 samples 
that passed were normalized in meffil using functional 
normalization using the top 20 control probe principal 
components and sample plate as a random effect.
At the same time point when the offspring were 
24 years old, information on smoking and e-cigarette use 
was obtained from a questionnaire that was completed by 
458 of the offspring with DNA methylation data. Ques-
tionnaire data were collected and managed using RED-
Cap electronic data capture tools hosted at the University 
of Bristol [43]. The participants were asked whether they 
had ever smoked or used an e-cigarette, as well as about 
the frequency and duration of use. From these details 
were determined three groups of participants: (1) vapers 
(currently users of electronic cigarettes or other vap-
ing devices, n = 14) (2) smokers (current daily or weekly 
smokers, n = 47) (3) non-smokers (smoked < 100 ciga-
rettes in their lifetime and never used an electronic ciga-
rette or other vaping device, n = 262).
We assessed the discriminative performance of a meth-
ylation score generated in SEE-Cigs for predicting e-ciga-
rette use (vs. non-smoking) in the ALSPAC cohort, which 
was compared with a methylation score for predicting 
smoking (vs. non-smoking). Both e-cigarette and smok-
ing methylation scores were obtained using the same 
approach described above in the full sample of: i) vapers 
vs. non-smokers and ii) smokers versus non-smokers, 
respectively, in SEE-Cigs.
The Cancer Genome Atlas
We used data on 27 individuals with lung adenocarci-
noma (LUAD) and 41 individuals with lung squamous 
cell carcinoma (LUSC) who had Illumina Infinium 450K 
DNA methylation measured in both tumour and adja-
cent normal samples as part of The Cancer Genome 
Atlas (TCGA). Again, a methylation score was generated 
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on the full sample of vapers versus non-smokers in SEE-
Cigs, this time restricted to CpG sites which were present 
only on the 450K array. This was compared with a meth-
ylation score for smoking generated on the full sample of 




Figure  1 shows the participant flow for the SEE-Cigs 
study. The final sample consisted of 117 smokers, 117 
non-smokers and 116 vapers with methylation data. 
Descriptive characteristics are displayed in Table 1. Com-
pared with non-smokers, vapers were more likely to have 
higher BMI, be male, have lower educational attain-
ment and be more exposed to household smoke. Smok-
ers were more likely to be male, have lower educational 
attainment, be more exposed to household smoke and 
to use drugs recreationally. Smokers were slightly older 
on average than non-smokers and vapers. The major-
ity of participants were of white ethnicity, with a slightly 
higher proportion of non-white individuals among the 
non-smokers. Smokers had smoked for a median of 1.20 
(IQR = 0.38–3.15) pack-years, while both non-smok-
ers and vapers reported a minimal smoking history. 
This was verified based on levels of AHRR methylation 
(cg05575921), for which 3 non-smokers and 5 vapers 
had < 60% salivary methylation, indicative of previous 
smoking (Fig.  2). There were no differences in cell type 
proportions of the saliva samples obtained from the par-
ticipants. Most vapers used e-cigarettes containing nico-
tine and vaped daily.
EWAS
7 CpGs were associated with vaping (vs. non-smoking) 
at p < 1 ×  10–5 and none at p < 5.91 ×  10–8 (Table  2). The 
top three CpGs were located in protein-coding genes for 
a ribonuclease P/MRP subunit (RPP14), an insulin-like 
growth factor receptor (IGF1R) and a gamma-aminobu-
tyric acid (GABA) A receptor (GABRP). After accounting 
for cell composition, smoking history, ethnicity and can-
nabis use, associations at the 7 CpGs weakened slightly, 
with the exception of signals at cg12435725 (RPP14), 
which strengthened with adjustment for self-reported 
smoking history (p = 9.02 ×  10–8) and AHRR methylation 
(p = 8.92 ×  10–8); cg02066693, which was stronger among 
individuals of white ethnicity (p = 6.27 ×  10–7); and 
cg12734956, which was stronger after excluding individu-
als with low levels of AHRR methylation (p = 3.27 ×  10–7) 
(Additional file  2: Table  1). 13 CpGs were associated 
with smoking (vs. non-smoking) at p < 1 ×  10–5 and one 
at p < 5.91 ×  10–8: cg05575921 located in AHRR encod-
ing the aryl hydrocarbon receptor repressor (Additional 
file 2: Table 2). 14 CpGs were associated with vaping (vs. 
smoking) at p < 1 ×  10–5, with the top association also at 
AHRR (cg05575921) (Additional file 2: Table 3). Methyla-
tion at cg05575921 was 8.2% (95% CI = 5.7–10.5) lower 
in smokers compared with non-smokers, and 7.1% (95% 
CI = 4.6–9.6) lower in smokers compared with vapers. 31 
Fig. 1 Participant flow chart for SEE‑Cigs
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Table 1 Descriptive characteristics of participant groups in this study
a Maximum sample sizes
Non-smokers
(n =  117a)
Smokers
(n =  117a)
Vapers
(n =  116a)
Mean (SD) Mean (SD) Mean (SD)
Socio‑demographic factors
 Age (years) (n = 348) 20.6 (3.5) 22.8 (4.9) 20.9 (4.3)
 BMI (kg/m2) (n = 345) 22.6 (3.5) 23.2 (4.2) 26.0 (6.8)
Median (IQR) Median (IQR) Median (IQR)
 Smoking (pack‑years) (n = 313) 0 (0, 0.0001) 1.20 (0.38, 3.15) 0.0013 (0.0006, 0.0027)
n (%) n (%) n (%)
 Sex (% male) (n = 350) 60 (50) 60 (50) 73 (80)
 Ethnicity (% white) (n = 344) 94 (80.3) 103 (88.8) 99 (89.2)
 Education (% higher education) (n = 344) 101 (86.3) 93 (80.2) 69 (59.5)
 Occupation (% unemployed) (n = 344) 5 (4.3) 10 (8.6) 21 (18.9)
 Household smoking (% yes) (n = 346) 47 (40.2) 79 (67.5) 76 (67.9)
 Recreational drug use (% yes) (n = 346) 7 (6.0) 31 (27.0) 11 (9.7)
 Cannabis (% yes) (n = 346) 5 (4.3) 23 (20.0) 10 (8.7)
Mean (SD) Mean (SD) Mean (SD)
Estimated cell type proportions (%) (n = 350)
 Buccal 48.3 (18.2) 49.4 (18.5) 45.4 (17.1)
 Bcell 1.7 (1.2) 2.1 (1.8) 2.2 (2.1)
 CD4T 0.2 (0.4) 0.2 (0.5) 0.2 (0.7)
 CD8T 0.001 (0.005) 0.04 (0.44) 0.03 (0.24)
 Granulocytes 47.3 (19.8) 45.4 (20.8) 49.1 (19.3)
 Mono 0.4 (0.7) 0.5 (0.9) 0.6 (1.0)
 NK 1.1 (1.4) 1.5 (2.6) 1.6 (2.3)
n(%) n (%) n (%)
Vaping characteristics
 E‑cigarette device (n = 113) N/A N/A
  Cigalike (1st generation) 2 (1.7)
  Tanks (2nd generation) 11 (9.4)
  Mods (3rd generation) 76 (67.3)
  Pods (4th generation) 17 (15)
  Other 7 (6.2)
 Frequency of use (% daily) (n = 113) 105 (92.9)
 Device contains nicotine (% yes) (n = 112) 108 (96.4)
 Increased nicotine concentration in the past (% yes) (n = 113) 16 (14.2)
 Length of time vaping (% > 1 year) (n = 113) 70 (62.0)
Mean (SD) Mean (SD) Mean (SD)
 Nicotine content (mg/ml) (n = 112) N/A N/A 5.6 (4.7)
 Liquid per day (ml) (n = 108) 7.8 (7.7)
n (%) n (%) n (%)
Smoking characteristics
 Cigarettes or roll‑ups (% roll ups) (n = 117) 87 (74.4)
 Frequency of smoking (% daily) (n = 117) 99 (84.6)
 Length of time smoking (% > 5 years) (n = 114) 52 (45.6)
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DMRs were identified in vapers versus non-smokers, 39 
in smokers versus non-smokers and 81 in vapers versus 
smokers. The top DMR identified between vapers and 
non-smokers comprised 9 CpGs in MUC4, with higher 
methylation in vapers compared with non-smokers (7.3% 
(95% CI = 5.7–9.0; p = 4.13 ×  10–18) (Additional file  2: 
Table 4).
Apart from associations at AHRR in the models involv-
ing smoking, there was limited overlap in the top CpGs 
identified in the three EWAS (Fig.  3, Additional file  1: 
Fig. 2 AHRR (cg05575921) methylation among participant groups < 60% methylation (shown in blue) is indicative of a substantial smoking history
Table 2 Differentially methylated CpG sites associated with e‑cigarette use versus non‑smoking
Model adjusted for age, sex, body mass index, educational attainment, household smoking, recreational drug use and 20 surrogate variables. n = 111 vapers, n = 117 
non-smokers
*p values < 1 ×  10–5
CpG site Chromosome Position Gene Symbol Beta SE p value*
cg12435725 3 58293450 RPP14 − 0.060 0.012 6.43 ×  10–7
cg02066693 15 99366135 IGF1R − 0.019 0.004 5.47 ×  10–6
cg14872828 5 170210761 GABRP − 0.035 0.007 2.77 ×  10–6
cg12734956 12 112181430 ACAD10 − 0.013 0.003 5.89 ×  10–6
cg02934082 3 122705793 SEMA5B − 0.036 0.008 5.92 ×  10–6
cg00388391 1 18459578 IGSF21 0.025 0.006 8.38 ×  10–6
cg10440286 22 37771664 ELFN2 0.044 0.010 9.31 ×  10–6
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Figure  2). 9 DMRs were found in common between at 
least two of the EWAS models (Fig.  3). One DMR was 
hypermethylated (chr20:BLCAP;NNAT) and two hypo-
methylated (chr20:SLC2A10 and chr3:THRB) in non-
smokers compared with vapers and smokers. Two DMRs 
were hypermethylated (chr10 and chr3:CACNA1D) 
and two were hypomethylated (chr17:BRCA1;NBR2 
and chr6:PRRT1;PPT2) in smokers compared with non-
smokers and vapers. Two DMRs were hypermethylated 
in vapers compared with smokers and non-smokers 
(chr10:ANXA11;LINC00857 and chr17:HSPB9;KAT2A).
For the 7 CpG sites associated with vaping (vs. non-
smoking), the direction of effect was consistent irre-
spective of vaping duration. The magnitude of effect 
was typically larger among those participants reporting 
to have vaped for > 1  year compared with those vaping 
for 6  months–1  year, with the exception of cg10440286 
(ELFN2). For the 13 CpG sites associated with smoking 
(vs. non-smoking), the direction of effect was consist-
ent irrespective of smoking duration. The magnitude of 
effect was larger among those participants reporting to 
have smoked for > 5 years compared with those smoking 
for 6 months–5 years at some (e.g. cg05575921 (AHRR), 
cg21732535 (PTH2R)), but not all (e.g. cg23771956, 
cg13159505 (RPTOR)) sites (Additional file 1: Figure 3).
Enrichment and annotation
There was strong enrichment of known smoking-related 
CpGs in the EWAS of smokers versus non-smokers 
(Wilcoxon test p = 1.05 ×  10–14 for Joehanes et  al. CpGs 
[10] and p = 1.10 ×  10–9 for Teschendorff et  al. CpGs 
[14]) (Additional file 1: Figure 4), unlike in the EWAS of 
vapers versus non-smokers (Joehanes p = 0.67, Teschen-
dorff p = 0.28) (Additional file  1: Figure  4). One smok-
ing-related CpG was found to be similarly methylated in 
vapers in GABRP (cg14872828; p = 2.77 ×  10–6).
One CpG previously associated with cannabis was 
found to be associated with e-cigarettes after Bonfer-
roni correction (cg04180046; p = 0.0029). This CpG has 
also been previously associated with smoke exposure 
[10], and there was no difference in methylation at this 
site between vapers and smokers in the present study 
(p = 0.865) (Additional file  2: Table  5). No CpGs pre-
viously associated with alcohol use were found to be 
associated with e-cigarettes after Bonferroni correction 
(p > 0.005) (Additional file  2: Table  6). We also found 
little evidence of associations between 14 CpGs previ-
ously found in relation to vaping [29] in any of the EWAS 
after Bonferroni correction (p > 0.01) (Additional file  2: 
Table 7).
Three of the seven CpGs associated with e-cigarettes 
have been identified in previous EWAS for smoking, 
Fig. 3 Comparison of epigenome‑wide associations studies. A EWAS for e‑cigarette use (vs. non‑smoking) and smoking (vs. non‑smoking). B EWAS 
for e‑cigarette use (vs. non‑smoking) and e‑cigarette use (vs. smoking). C EWAS for smoking (vs. non‑smoking) and e‑cigarette use (vs. smoking)
Page 10 of 13Richmond et al. Clin Epigenet          (2021) 13:183 
Down Syndrome, systemic corticosteroid, prostate can-
cer, gestational age and fetal versus adult liver (Additional 
file 2: Tables 8 and 9). We found limited enrichment for 
KEGG pathways or GO terms (false discovery rate, FDR 
p > 0.05) (Additional file  2: Tables  10–13). In relation to 
e-cigarette use, response to ethanol/alcohol, positive 
regulation of insulin secretion and GABA transport were 
the top GO terms. Butanoate metabolism, synaptic vesi-
cle cycle and GABAergic synapse were the top KEGG 
pathways.
Methylation scores for smoking
All of the methylation scores for smoking were corre-
lated with reported pack-years smoked (|r|= 0.21–0.52, 
p < 0.0001), except the Teschendorff score [14] (r = 0.07, 
p = 0.19) (Additional file  2: Table  14). All of the scores 
differed between the smokers versus non-smokers 
(0.40–0.90 SD), and vapers versus smokers (0.37–0.86 
SD). While neither the Joehanes [10] nor the Teschen-
dorff score [14] differed between vapers versus non-
smokers, higher levels of the other three scores (Lu [33], 
McCartney [16], AHRR) were observed in vapers versus 
non-smokers (0.21–0.30 SD) (Table  3). However, these 
associations attenuated when reported smoking history 
was included in the model (Additional file  2: Table  15). 
Associations were similar in analyses restricted to indi-
viduals of white ethnicity (Additional file 2: Table 16).
Methylation scores for epigenetic ageing
Epigenetic age estimates were strongly correlated with 
chronological age (r = 0.49–0.70, p < 0.0001) (Additional 
file  2: Table  17). There was little difference in estimates 
of epigenetic age acceleration (EAA) between the three 
groups, except for GrimAge, where smokers had higher 
EAA relative to both vapers (2.5, 95% CI = 1.4–3.6 years) 
and non-smokers (2.6, 95% CI = 1.4–3.7 years) (Table 3). 
Associations persisted in analyses adjusting for a methyl-
ation score for smoking pack-years [33] (Additional file 2: 
Table 18) and when restricted to individuals of white eth-
nicity (Additional file 2: Table 16).
Methylation scores for e-cigarette use
We generated methylation scores for predicting e-ciga-
rette use (Additional file  2: Table  19). These performed 
poorly at discriminating vapers from non-smokers in 
both the internal (AUC = 0.55, 95% CI = 0.41–0.69) and 
external validation sets (AUC = 0.57, 95% CI = 0.36–
0.74). This was in contrast to the high discriminative per-
formance of the smoking scores (internal AUC = 0.80, 
95% CI = 0.69–0.91 and external AUC = 0.80, 95% 
CI = 0.72–0.88; Additional file  1: Figure  5). The smok-
ing and e-cigarette methylation scores performed poorly 
at discriminating tumour from adjacent normal tissue 
in lung adenocarcinoma (LUAD) cases (AUC = 0.57, 
95% CI = 0.40–0.73 and 0.58, 95% CI = 0.42–0.74). The 
e-cigarette methylation score also performed poorly at 
discriminating tumour from adjacent normal tissue in 
lung squamous cell carcinoma (LUSC) cases (0.64, 95% 
CI = 0.52–0.76). Moderate discrimination was observed 
from the smoking methylation score in LUSC cases (0.73, 
95% CI = 0.61–0.85) (Additional file 1: Figure 6).
Discussion
Among 117 smokers, 117 non-smokers and 116 vapers 
with a limited smoking history, we found that sali-
vary methylation signals of e-cigarette use were weak 
Table 3 Differences in DNA methylation scores between participant groups
Adjusted for age, sex, body mass index, educational attainment, household smoking and recreational drug use
a Coefficients = SD unit difference in score between groups; bcoefficients = difference in years betweengroups






Coefficient (SE) p value Coefficient (SE) p value Coefficient (SE) p value
Smokinga
 Joehanes [10] 0.62 (0.15) 4.39 ×  10–5 0.13 (0.15) 0.360 − 0.59 (0.14) 3.25 ×  10–5
 Teschendorff [14] 0.40 (0.16) 0.010 0.12 (0.14) 0.864 − 0.34 (0.15) 0.024
 Lu [33] 0.65 (0.11) 7.9 ×  10–9 0.30 (0.10) 0.002 − 0.47 (0.13) 1.98 ×  10–4
 McCartney [16] 0.83 (0.13) 2.14 ×  10–10 0.30 (0.12) 0.012 − 0.68 (0.13) 3.67 ×  10–7
 AHRR [25] − 0.90 (0.13) 1.12 ×  10–11 − 0.23 (0.11) 0.028 0.82 (0.14) 1.62 ×  10–9
Epigenetic  ageb
 IEAA [34] − 0.02 (0.68) 0.981 − 0.08 (0.64) 0.907 0.41 (0.67) 0.538
 EEAA [37] 0.91 (0.73) 0.212 0.38 (0.69) 0.578 − 0.68 (0.69) 0.325
 PhenoAge [36] 0.26 (0.81) 0.751 − 0.20 (0.86) 0.816 0.11 (0.85) 0.897
 GrimAge [33] 2.57 (0.59) 1.36 ×  10–5 0.74 (0.55) 0.179 − 2.41 (0.57) 2.09 ×  10–5
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and largely distinct from those established in relation 
to cigarette smoking. The top 3 CpGs for vaping were 
located in protein-coding genes for a ribonuclease P/
MRP subunit (RPP14) (p = 6.43 ×  10–7), an insulin-like 
growth factor receptor (IGF1R) (p = 5.47 ×  10–6) and a 
gamma-aminobutyric acid (GABA) A receptor (GABRP) 
(p = 2.77 ×  10–6). The top DMR was located in MUC4 
encoding Mucin 4 (p = 4.13 ×  10–18), an integral mem-
brane glycoprotein present in mucus upregulated in 
vapers [44]. Of the DMRs found to be differentially meth-
ylated in vapers compared with both smokers and non-
smokers, ANXA11 suggestively plays an important role in 
lung function, and variation in this gene has been asso-
ciated with Sarcoidosis (mainly affecting the lung) [45] 
and Chronic Obstructive Pulmonary Disease-related 
biomarkers [46]. Ethanol/alcohol, positive regulation of 
insulin secretion, GABA transport and butanoate metab-
olism were among the most enriched pathways, reflect-
ing biological responses to e-cigarette constituents (ethyl 
alcohol, ethyl butyrate and nicotine). Methylation scores 
for smoking and biological ageing were similar between 
vapers and non-smokers. Higher levels of a biologi-
cal ageing score (GrimAge) were observed in smokers. 
Finally, a methylation score generated to index e-ciga-
rette use poorly discriminated vapers from non-smokers 
in SEE-Cigs and in an independent dataset (ALSPAC), 
which was in contrast to a methylation score generated 
to index smoking. The smoking methylation score also 
showed better discrimination of tumour and adjacent 
normal tissue in lung squamous cell cases compared with 
the e-cigarette methylation score.
In contrast to our findings, two studies (comprising 
32 and 45 participants, respectively) found associations 
between e-cigarettes and methylation levels which over-
lap with smoking-related signals [29, 47]. We were also 
unable to replicate methylation differences for 14 CpGs 
previously related to e-cigarettes [29]. However, it is 
important to highlight that the vapers included in the 
previous studies were not selected for smoking history 
as stringently as in the current study and former smok-
ers were likely to comprise a substantial proportion of the 
sample.
Two studies showing a weak methylation profile related 
to smokeless sources of nicotine are supportive of our 
results [48, 49]. However, both studies only investigated 
peripheral blood and not tissue-specific methylation at 
the site of exposure (e.g. saliva).
Acceleration of a biological ageing methylation score in 
smokers but not vapers is of interest since such markers 
are predictive of age-related disease and mortality inde-
pendent of chronological age [37, 50, 51]. Discrimination 
of lung tumour and adjacent samples by a salivary-based 
methylation score for smoking is supported by previous 
findings [14]. The lack of discrimination by the e-cigarette 
methylation score could indicate that smoking-related 
methylation changes may be more relevant to tumouri-
genesis than changes related to e-cigarettes. However, 
the smoking methylation score generated in the present 
study was lower in lung squamous cell carcinoma rela-
tive to normal tissue, the inverse of what was expected 
due to higher levels being observed in smokers [14]. We 
have previously found methylation in tumour tissue is 
in the opposite direction to that observed in relation to 
smoking for AHRR (cg05575921) [52] (Additional file 1: 
Figure 7), the CpG contributing most weight to the meth-
ylation score for smoking (Additional file 2: Table 19).
Major strengths relate to the design of the study, 
including the recruitment of individuals with a limited 
smoking history and the assessment of methylation lev-
els in an easily accessible and exposure-relevant tissue 
for investigating epigenetic profiles of e-cigarettes. Limi-
tations include the representativeness of our study sam-
ple, with demographic characteristics different to the 
general population due to the strict inclusion criteria. 
The young age of the study sample (mean age = 21 years) 
and limited smoking and vaping history could hamper 
the detection of methylation signals. This may explain 
why so few CpGs were identified in relation to smoking 
than anticipated based on previous studies of oral sam-
ples [14]. Nonetheless, enrichment of smoking-related 
CpGs among the smokers indicates that these signals 
were present but more weakly associated. Furthermore, 
small sample size could have hindered the detection and 
replication of e-cigarette methylation signals, in particu-
lar in the external validation analysis in ALSPAC where 
methylation data was only available on 14 vapers. Simi-
lar enrichment for smoking-related CpGs was not found 
among the vapers, indicating that the methylation signa-
ture of e-cigarettes is distinct from that of smoking, and 
that vapers in the present study were accurate in report-
ing their limited smoking history, despite this not being 
biochemically verified.
While it appears that the methylation profile of vapers 
is less pronounced than that of smokers, the methylation 
changes associated with e-cigarettes may be commen-
surate in scale with other lifestyle exposures and repli-
cation of the signals identified in relation to e-cigarettes 
in larger studies is warranted. In addition, future studies 
may benefit from comparing saliva methylation patterns 
in e-cigarette users with those from other sample types, 
such as blood, since some markers may perform better as 
predictors when measured in whole blood [18].
Additional research in cohort studies is required to 
investigate methylation changes among ex-smokers quit-
ting with different methods, including e-cigarettes. While 
findings from this study suggest that e-cigarettes may 
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have distinct health effects from cigarettes, we cannot 
provide robust conclusions regarding the safety of e-cig-
arettes. Furthermore, although the methylation changes 
identified in relation to both smoking and e-cigarettes 
may be predictive of future disease risk, the causal con-
sequences of these methylation changes on health out-
comes are currently uncertain [52].
Conclusions
Findings from this study suggest that e-cigarette use 
does not impact saliva methylation in the same way as 
cigarette smoking. Unlike for smoking, the methylation 
profile for e-cigarettes did not replicate in independent 
samples and was not able to discriminate cancer from 
normal tissue. However, the short duration of e-cigarette 
use by the study participants and sample size may have 
hampered the detection of signals. Further studies are 
required to detect a robust methylation signature for 
long-term e-cigarette use. The extent to which meth-
ylation related to e-cigarette use translates into chronic 
effects and relevant health outcomes should also be 
investigated.
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